Q1 2023 Model N Inc Earnings Call
Greetings and welcome to Model N's first quarter fiscal 2023 earnings conference call. At this time all part of events are in a listen-only mode. The question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference please press star zero on your telephone keypad. As a reminder this conference is being recorded. It is now my pleasure to introduce your host Carolyn Bass investor relations.
Thank you, you may begin good afternoon. Welcome to model end's first quarter and fiscal 2023 earnings call. This is caron bass Investor Relations for model an.
With me on the call today are Jason Blessing, Madeline's Chief Executive Officer, and John Etterer, Chief Financial Officer.
Our earnings press release was issued at the close of market and is posted on our website.
The primary purpose of today's call is to provide you with information regarding our first quarter of fiscal 2023 performance and offer an outlook for our second quarter and fiscal year ending September 30, 2023.
The comments made on this call may include forward-looking statements.
These forward looking statements are based on management's current views and expectations as of today and should not be relied upon as representing our views as of any subsequent date.
We display any obligations to update any forward listing statements or outlook. Actual statements made different materially. Please refer to our risk factors in our most recent form 10Q followed with the SEC.
In addition, during today's call, we will discuss non-GAAP financial measures.
These non- GAAP financial measures should be considered in addition to not as a substitute for or an isolation from gap results.
Reconciliations of the non-GAAP metrics to the nearest GAAP metrics are included in the earnings release we issued today, which is available on our website.
I encourage you to visit our Investor Relations website at investor.modeln.com to access our first quarter fiscal 2023 press release, periodic SEC reports, and the webcast replay of the call today.
Finally, unless otherwise stated, all financial comparisons in this call will be made to our fiscal year 2022 results.
And with that, let me turn the call over to Jason.
Thank you, Carolyn, and welcome to our call today. I am pleased to report that our first quarter results beat expectations on total revenue and subscription revenue, and professional services came in at the high end of our guidance range.
I am very proud of our team and the strong quarter that we posted to start the year.
As we look ahead, we remain committed to driving profitable growth throughout the year.
I'd like to highlight two important Q1 metrics that stand out to me.
First, our SAS ARR group by 36% year-over-year.
In addition, our remaining performance obligations or RPO, which reflects the strong visibility into our business, grew 32% year over year.
In short, we had a good start to our fiscal year.
Now I'd like to share some of the business highlights from the quarter. Success in Q1 was driven by a healthy contribution from all areas of the business.
We signed new logos, closed a meaningful new SAS transition, saw numerous customer base expansions, and we also enjoyed strong renewals across the board.
Starting with SaaS transitions, during the quarter, we signed a top 10 global pharma company and a long time Model N customer to begin their cloud journey with us.
Our SaaS platform will allow them to take advantage of Model N innovations more quickly and cost-effectively, as well as give them access to the latest regulatory updates.
This win is just the latest example of Model End's industry standard revenue management and compliance platform helping global pharma companies to operate more efficiently.
I am personally sitting on the steering committee for this project and look forward to partnering with this customer to achieve their model and objectives.
In Life Sciences, we also posted wins with several new logos. In Q1, we signed Lanthius as a customer.
Lantius is an established leader in the development, manufacture, and commercialization of AI-powered diagnostic and therapeutic products.
Lampea sought a best of breed solution to address their revenue optimization and compliance challenges, which had grown in scale and complexity due to acquisitions and new product launches.
This win includes US government and commercial contracting as well as state price transparency management.
This suite of products is critical to managing the increasingly complex regulatory environment, while also helping our customers maintain commercial and regulatory compliance.
Model N was also selected because of our deep experience in global pricing and our successful track record of integrating with SAP.
During Q1 we also signed Kate Farms as a new logo.
Cape Farms offers products that help support the nutritional needs of people with a variety of critical health issues.
K-Farms require a comprehensive solution to help their flexible approach to contracting and pricing, as well as the system to help with compliance, membership management, and tracking chargebacks and rebates.
They selected Model N based on our industry-leading solutions, our domain expertise, and track record for quality project delivery.
This win also shows our ability to expand to a close adjacency to our core pharma market.
During the quarter, we also enjoyed strong expansions in our life sciences customer base.
One such example is at AbbVie, a top 10 global pharma company.
Following the mega merger of pharma giants AbbVie and Allergan, AbbVie expanded their investment with us to fold Allergan into AbbVie's Model N platform.
This is another great example of where Model N is once again being chosen as the standard for a top 10 global pharma company that is growing organically and through M&A.
Turning to high tech, we continue to leverage our leadership position in the semiconductor industry by extending into other adjacent segments.
Further, our Land and Expand strategy is paying dividends and during Q1 we closed several upsell opportunities in high tech.
One example is at Soledigm Technology, a global provider of flash drive technology that was spun out of Intel.
At the time of the spin-out, Solidine selected Model N as one of their core business systems.
After successfully going live on Revenue Cloud and data management, Solodyme has continued to expand their usage of Revenue Cloud and recently added global pricing and deal management modules. As you may recall, we signed Solodyme as a new customer just a year ago, and it's great to see this global company live on Model N and continuing to expand.
expanded their model and footprint by adding additional channel data management partners to support their ongoing growth.
N-phase is also a great example of how our high-tech solutions can be leveraged in adjacent markets that involve complex technical components and distribution channels similar to the semiconductor industry.
Turning to professional services, our team had another very strong quarter to kick off the fiscal year.
Professional services demand remains near an all-time high, and our backlog continues to be very robust.
Following Model N's latest product release, we had several customers take this update during the quarter and successfully go live.
This update includes a new payment management solution for high tech companies, as well as improvements to our global price management application for pharmaceutical and med tech companies. A large cohort of our customers went live on this update during Q1, which once again proves out our core SaaS value proposition of keeping.
As you know, Moderna is a leading pharmaceutical and biotechnology company that focuses on combating disease by leveraging its mRNA vaccine platform.
As Moderna's business grew during the pandemic, they needed a solution to help them scale their revenue management processes.
We started our journey with Moderna in EMEA with global price management and international reference pricing, which helps companies make more informed decisions on how to price and sequence product launches across countries.
Moderna then added our global tender management product to more effectively distribute their products in EMEA.
Then in Q1, Moderna turned to Model N Business Services to support its US commercial operations.
This is a great illustration of how we can land and expand, and how our flexible delivery model allows us to tailor solutions based on how a customer wants to consume our revenue management products.
During the quarter, we also released our fall 2022 product update. This latest release demonstrates our commitment to continued investment in our industry leading products and to deliver continuous innovation to our customers on our cloud platform.
Highlights of this release include a new customer value dashboard that shows real-time savings and processing volumes in Model N. This is a great example of us delivering on our data and analytics vision.
We also delivered enhanced features to help farm companies better manage drugs coming off patent protection.
We made several regulatory updates to support Medicaid changes.
And we also delivered a new analytics application to help better visualize deal profitability.
Finally, earlier today, we issued our new 2023 State of Revenue report.
This marks our fifth annual report which identifies pressing challenges and opportunities for pharmaceutical, medtech, and high-tech manufacturers.
This report is based on the results of a survey of more than 300 C-suite executives directly responsible for revenue management.
As organizations continue to navigate the current economic climate, the quality and reliability of technology solutions are more important than ever.
The top three highlights from this year's report include supply chain disruption is the number one theme impacting revenue management for the second year in a row.
Second, 70% of executives believe their industry is losing billions of dollars due to issues like inaccurate or ineffective pricing and quoting.
And finally, 96% report that staffing and expertise issues negatively impact their revenue management processes.
These insights help us understand how to empower our customers to create and bring their life-changing products to market.
I encourage all of you to read the 2023 State of Revenue report by downloading it from our website at modeln.com.
Let me conclude by saying that I'm pleased with our continued execution in this environment and I am proud of the strong SaaS ARR growth that we posted while also showing leverage on our bottom line.
I would also like to thank our customers who continue to partner so closely with us.
And of course, these great results are a reflection of the great model and mentors around the world and their dedication to our deracor values and company culture.
We kicked off the year with a solid Q1, and I am excited about the year ahead.
With that, I will now turn the call over to John to discuss our Q1 financial results and provide guidance for Q2 and fiscal year 2023.
John
Thank you, Jason. And good afternoon to everyone on the call today. As Jason noted, we had a solid start to fiscal 2023, and we believe that we are right on track for the full year.
The first quarter was a continuation of the key themes that we've been highlighting about the business. One, our balanced approach of delivering both revenue growth and improving profitability. And two, the emerging strength of our underlying SAS business as demonstrated by our SAS ARR growth, net retention, and RPO growth.
Looking specifically at our financial results for the first quarter, total revenue grew 15% to 59.2 million, which exceeded the top end of our guidance.
Description revenue increased by 16% to 44.2 million and also exceeded the upper end of our guidance range.
Lastly, professional services revenue grew by 11% year over year to $14.9 million and was at the upper end of our guidance range.
In terms of our profitability, please keep in mind that we'll be discussing non-GAAP numbers and a full reconciliation of our results is provided in our earnings release.
For the first quarter, total non-GAAP gross profit was $36.1 million, representing a gross margin of 61% vs. 60.3% in Q1 last year, an improvement of 70 basis points.
Non-GAP subscription gross margin continued to improve hitting 69.3% compared to 67.6% in Q1 of the prior year. ASSAS revenue increased as a percentage of total subscription revenue.
non-GAAP professional services gross margin was 36.2% compared to 39.7% in Q1 last year. As we have said for several quarters now, operating north of 40% gross margins on our professional services business was not sustainable. We would expect this year to be more in line with what we saw in Q1.
As Jason mentioned, this is not a change in demand. In fact, our professional services backlog remains robust.
but rather the challenges managing the mix of resources required for specific projects and avoiding overutilization.
Adjusted EBITDA was $9.1 million, an increase of 27% from the first quarter of fiscal 2022 and within our guidance range. Adjusted EBITDA margin improved to 15.4% compared to 14% in the first quarter last year. And finally, non-GAAP net income was $8.7 million or 23 cents per share.
which was at the high end of our guidance. Key driver of our results in the first quarter and our business overall is the accelerating transition to SAS revenue.
as we are benefiting from SaaS transitions. In addition, our SaaS net retention number hit 134% in Q1, which reflects our ability to successfully cross-sell and up-sell customers, but it is also getting a boost right now from SaaS transition activity. As we noted on our last call, SaaS revenue represented 60% of total subscription revenue for the full year of fiscal 22. In Q1, this ratio improved, with SaaS revenue contributing 66% of our total subscription revenue, another proof point that our transition to SaaS is accelerating. In terms of the balance sheet,
We ended the quarter with $175.2 million in cash and equivalents, which was down from the end of September , but in line with our typical Q1 seasonality due to the timing of our annual bonus payouts and the biannual interest payment on our convertible debt.
Current deferred revenue of $67.1 million was up $4.8 million sequentially versus Q4, and up $9.1 million versus last year. At a high level, we've been seeing increases in SaaS deferred revenue partially offset by declines in maintenance deferred revenue. As a reminder, deferred revenue can fluctuate depending on invoice and cycles.
million, which was up 32% on a year-over-year basis.
The current portion of our RPO balance was up to $144.5 million, representing growth of 17% year-over-year.
A key driver of our total RPO has been the success we've been having with SaaS transitions, which tend to be larger, longer term deals.
In terms of our outlook for the remainder of fiscal 2023, for the second quarter, we expect total revenue to be in the range of $59 to $60 million, with subscription revenue in the range of $43.5 to $44 million, and professional services revenue in the range of $15.5 million.
to 16 million. We expect adjusted EVA dot to be in the range of 6 to 7 million. For non-GAP EPS, we are expecting a range of 15 to 18 cents per share based on a fully diluted share count of approximately 43.3 million shares.
For the full year of fiscal 2023, we are raising our outlook for subscription revenue and total revenue, reflecting the strong SAS performance in Q1, and reiterating our guidance for adjusted EBITDA and non-GAAP earnings per share, which calls for continued margin improvement versus last year.
In summary for fiscal 23, we expect total revenue to be in the range of $242 to $245 million.
Subscription revenue to be in the range of $179 to $181 million.
professional services revenue to be in a range of 63 to 64 million.
We expect adjusted EBITDA to be in the range of $37 to $40 million and non-GAAP EPS to be in the range of $0.90 to $0.97 per share based on a fully diluted share count of approximately 43.7 million shares.
A few reminders regarding our guidance for the second quarter and fiscal 2023.
First, there are some seasonal elements to the second quarter, including two fewer days of subscription revenue compared to Q1, and increased expenses for payroll taxes and other benefits.
Second, we adopted new accounting standards at the start of the fiscal year with regards to our convertible debt. And the fully diluted share count includes approximately 5 million shares for the as-if converted method versus the traditional treasury method.
Finally, our guidance reflects the ongoing transition of our business model, which is driving accelerated SaaS ARR growth, but partially offset by steeper declines in maintenance revenue. On our earnings call last quarter, we noted that we expect maintenance revenue to decline by 30% or more in FY23.
Well, we do not provide specific guidance on SAS ARR. We do expect the growth rate to be at an elevated level, again in Q2 due to SAS transitions and an easier comparison to last year, with more moderated growth in Q3 and Q4 as a year-over-year comparisons get more difficult.
For the full year, we expect SAS ARR growth to be comfortably above our long-term target of 20%. For more information, visit SAS.org
We also expect SAS net retention to follow a similar trend as SAS ARR growth over the course of this year.
In summary, we executed well in Q1 and believed that we were on track for the year. We continued to build strong momentum in our SaaS business as evidence by SaaS ARR growth, SaaS net retention, and RPO metrics, and we remain committed to continued improvement on profitability.
With that, I'll turn the call over to the operator for any questions.
Thank you. Ladies and gentlemen, at this time we will begin documenting a question and answer session. If you'd like to ask a question you may press star one on your telephone keypad.
A confirmation tunnel indicate your line is in the question queue. You may press star 2 if you would like to remove your question from the queue.
for participants using speaker equipment, it may be necessary to pick up your handset before pressing the star key.
Our first question comes from the line of Matt Van Vliet with BTIG. Please proceed with your question.
Yeah, good afternoon. Thanks for taking the question. I guess when you look at the remaining pipeline of potential SaaS transitions for existing customers, how much of the overall work loads out there and you feel like you've gotten through.
And maybe more importantly as you announced, you know, another new top 10 pharma here, any major logos that you haven't yet gotten to migrate that we should think about going forward.
Hey, Matt, good afternoon. This is Jason. I'll answer that. So, yeah, a couple data points I'll share. So, as we talked about at the beginning of last fiscal year, we were at 50% of our customers who had either transitioned or started their transition. And then just a quarter ago, we said that number was now 70%. And so, you know, we've got 70% plus now with this quarter.
25 to 30% to move this year and that we've got pretty good visibility into that. So, you know, we continue to make progress. This was an important quarter for us because it was one of our few remaining top 10 customers to move and that we just continued to be bullish on the progress that we've made on SaaS transitions and the...
the efficiencies and sort of future-proofing the platform are there that maybe it's speeding things up. Due to the macro, just kind of curious on how the overall economy is impacting the decision-making.
Yeah, certainly with respect to SAS transitions, you know, the macro has not become an issue in those discussions.
Farmer companies just cannot afford to go unsupported on one of their core regulatory compliance platforms. So Sass transition certainly continued to be prioritized very highly within our customer base and you know, maybe just a Comment more broadly on macro. You know, we certainly haven't seen any major changes in
So, not a huge impact for us in our first quarter.
All right, great, thank you. Our next question comes from the line of Joe Verwink with Robert W. Baird. Please proceed with your question.
Hi, everyone. Maybe I'll start going back to the anecdote on Medirna choosing business services as quarterly. How common does that tend to be? I guess the question is, uptake of business services within revenue cloud install base and then...
Maybe part B to the question one thing that popped up in the state of revenue report was I think added Constraints when customers are asked about the available Consultant or grant contracting resources they they have out there
Do you think that might actually weed more potential customers your direction from to have an established franchise that can provide those services? Hey Joe, this is Jason. That's actually a great question. We have actually started to see this pattern materialize. We have started to see this pattern materialize.
around a mix of business services and software products in the customer base. Moderna is not the first. We've had a few previously. We've also talked about, I'm not sure what logos we've mentioned, but we have started to see this pattern in the base.
Moderna was interesting because their global tender management use in Europe is being driven out of a fairly well-staff Strong tenders group there, but the market access function here in the US is fairly nascent Believe it or not for Moderna and so the business services proposition
a value proposition resonated very strongly with them. And then yeah, it's interesting you pick up on that people component of the state of revenue report. And as I said and as John said, we continue to see very strong demand for our services across the broader portfolio of services that we offer.
and customers really are coming to us for that domain expertise and as a strategic addition to their teams to help them with their needs.
That's great. And then I'll stick with the state of Revenue report because there is just a lot of detail in there. A few things that I thought were interesting actually pertained to how customers could be using more of model end. So I suppose this is a Nav retention question ultimately. Bye.
Two specific areas that were highlighted. One is that by geography, you tend to use a dedicated solution for that geography. So that kind of one consolidated or platform resource. And then second was just the overall interest around analytics associated with your revenue management.
I would guess that these are relatively small contributors to that retention today. Where does this go? Could these be bigger contributors in some sort of near-term timeframe? I'll make a couple of qualitative comments on that. As we've talked about in past calls, we've definitely been investing in Europe .
and then move to your excuse me move to the US and so
It is not atypical to have the buying geographically centralized like we we saw in those two cases and so having dedicated products and teams that Concaitor to those needs It is certainly important and then I would say you know on the analytics from we haven't even scratched the surface of that yet
that we offer and I think is a great example of what's to come. And coincidentally, that was actually one of the initial products that we landed at with Moderna in Europe . So when you look at the net dollar retention today, as Joan talked about in his remarks, you know, it was getting a little bit of a boost from SaaS transitions.
it's getting a boost from a lot of the cross-selling upsell that we pull through on SAS transitions, but in terms of major geographic expansion and analytics, that's really, I think of that more as a future opportunity and something that's not really driving that number today.
Okay, very good. I'll leave it there. Thank you.
Okay, very good. I'll leave it there. Thank you.
Our next question comes from the line of Chad Bennett with Craig Hallum. Please receive with your question.
Great, thanks for taking my questions. Nice job again on the quarter. So just Jason, I don't think I've heard a ton from you or a lot from you on adjacencies in life sciences and in high-tech and I know you pointed out a couple on the call that looked very interesting. Can you talk about...
I know you've been, you know, laser focused on, on the core life sciences biz and core semi high tech biz since you got there, but it seems like something that's opening up a bit.
Yeah, it's a good question, Chad. I appreciate you noticing that as well from the script. I guess there's a couple of things I would say. I mean, first and foremost, we're excited about the white space in our customer base and high-tech and life sciences as it exists today. We remain excited about new logos and geographic expansion as it exists in our wheelhouse today.
the winds that I talked about today as not even a full standard deviation away from the markets we're in today. If you look at life sciences and some of the pattern recognition, our products play well in life sciences where things are heavily regulated and there are complex incentives.
to distribute and reward the channel for those products. And then on the high-tech side, if it's a highly engineered product that's distributed through a multi-tiered channel, complex multi-tiered channel, the high-tech products are a pretty good fit for that.
that pattern. And so these customers that come in, we're opportunistic about them. And if they fit with the patterns and the situations where we know we can win, we will pursue them. And that's some of these early returns have been good.
Got it. I appreciate. Maybe one for John . Just in terms of the cadence of SAS ARR for the rest of the year, should we think about it similar, whether it's seasonally, sequentially, as to last year? And then if you look at it from a net new SAS ARR standpoint, I mean, you put up a
Very good. Net new SAS AR quarter and the December quarter. Does net new SAS AR are grow year over year in the next three quarters? Any way you want to address that one. Thanks. Yeah. Thanks, Chad.
Maybe I'll just reiterate a couple of the comments that we made up front and trying to address your question that way. I think that we want to stay just shy of providing very specific guidance on SAS ARR, but we did want to try and provide some color commentary in terms of how we see the year laying out. And over the last, this actually goes back over the last couple of quarters.
We've seen SAS AR growth accelerating as we've been benefiting from SAS transitions in particular. And so the last few quarters you've seen that number tick up hitting 36% year over year growth in Q1. Our long-term target, as you know, is 20%. But as we look at the course of this year.
We do expect to be at an elevated level again in Q2, where we also have an easier year-over-year comparison to Q2 of last year. But then as we get out to Q3 and Q4 of this year, the comparisons do get a little bit tougher for that year-over-year growth number. And so we would expect it to moderate a little bit based on those comparisons over the second half of the year. Here.
And then I just add, you know, similarly, we would expect the SAS net dollar retention metric to follow the same type of trend. And so we would expect to see that a little bit elevated as it was in Q1 and over the first half of the year, and then moderate a little bit over the second half of the year. Got it. And then maybe, sorry, one last quick one for.
much.
Yeah, no thanks for the question. So, you know, a couple of things there. So, first, you know, what we saw in Q1, I would say largely reflected the increased mix that we're getting from SAS revenue. And so, when we look at that total subscription line, the SAS piece of it is...
is at a higher margin and so an improving mix there helps us and that was the couple points that you saw of improvement in Q1 this year versus Q1 last year. One thing I would caution you on over the balance of this year, we do have of course headcount related expenses that hit that line our cloud hosting team and our support organization.
And in Q2, we do have a seasonal uptick in headcount related expenses for payroll taxes and things like that. So that will impact that line also. But in general, we're making good progress and a lot of it has to do with the shift to SAS. Got it. Thank you much. Nice job again. Thanks, Chad. Our next question comes on the line of Joe Mears. We're truest. Please.
current customers as well. Yeah thanks for the question Joe. So you know as we've reported the last few quarters since we partnered with Pfizer to build and release this product demand has been has been strong and we continue to see new states enacting state price transparency rules and even more importantly they're now stepping up enforcement over the last year and the forecast is for enforcement to continue to be pretty robust over the next couple years so as our existing customers and our new logo pipeline you know they're definitely turning to us and looking at this product and I would say state price transparency management in new logos is you know if it's not a part of every deal.
These are material percentage revenue right now and what they could be exiting.
That's your answer in the questions.
Yeah, certainly global price management and global tender management are both TIFI project products and an important way that we land. Global price management, as the name implies, is used by our customers to manage their price list in both the US and rest of the world, and specifically in Europe . So...
The product market fit for that product is pretty much universal for global pharma companies. And so that is a product that's quite honestly it's been a good seller for us over a number of years now. That's not a new product. Global tender management is really tailored for geographies where...
pharmaceutical purchasing processes are run through centralized health ministries through a tendering process. And so Europe is really the first geography that we focused on. That's a relatively newer product and demand has been brisk for it because it is tailored again specifically to pharma companies. And as we talked about, we've landed some big new logos with that combination that one too punch up.
Our next question comes from the line of Ryan McDonald with Needham & Company. Please proceed with your question.
Thanks for taking my questions and congrats on IAC's quarter. Jason, you talked about the AbbVie Allergan deal in the quarter and also in the Q&A about sort of the excitement you have, sort of the opportunity within the existing base. Just curious, given all the M&A that we've seen over the past few years here.
what the expansion opportunity looks like from just purely M&A deals and what you've historically seen in terms of when that opportunity comes to the table post that acquisition.
That's a good question, Ryan. On the balance, we have benefited from M&A and a typical pattern that we will see, and this is the case with Allergan and Abbey, and you know, we've seen this with others as well, that the two companies will not have the exact same footprint of Model N, and so the M&A transaction is a cash.
cross-sell and up-sell opportunity for us.
That's helpful and then maybe one for John . John on the updated guidance you talked about some of the moving parts in terms of seasonality within the business and maybe some higher payroll taxes as we look at that adjusted EBITDA guide for second quarter is that the I guess the step down in second quarter is that primarily
being covered by the additional tax payments or if there's other incremental investments that you're perhaps pulling forward into the second quarter that's going to hit then versus the back half. Thanks.
Sure yeah no maybe a couple of different threads in there so first just with reflect to the guidance itself it's really two factors one is as actually on the revenue side of things we have two fewer days of subscription revenue so you bun Recognition for that
That costs us in round numbers about a million dollars of subscription revenue. The second piece is related to the expenses and that's due to Q1 or pardon me Q2 being the first calendar quarter of the year and so we have higher payroll taxes and other benefits compared to the December quarter. So it's really those two factors that are that are rolling into that. And then just in terms of operating expenses more generally.
We have been making select investments in the business and I think if you go back and look at our results over the last couple of quarters, probably starting in fiscal Q3 last year and then looking sequentially in Q4 and Q1, you'll see that we've been making investments in R&D and sales and marketing in particular, so we continue to focus on the product and sales capacity.
And those are underlying our model as well. Excellent. I appreciate the clarification there. Sure.
Our next question comes from the line of Joe Goodwin with JMP Securities. Please proceed with your question.
Great, thank you so much for taking my questions. John , did you disclose the amount of maintenance revenue you had in the first quarter? I apologize if I missed that.
We did not update that, so we'll just do that on an annual basis. And so at the end of fiscal 22, I believe we had 17.5 million in maintenance revenue. And we did indicate on our last call that we thought maintenance revenue would be down 30% or more this year.
and maybe how we should think about that going forward.
Yeah, I'm not sure where your $20 million number comes from. That's not something that we've disclosed in the past. But what I would say is that we do still have some term license activity in the subscription line. It's gotten down to a pretty small level, frankly.
that they leverage different revenue management systems across different regions. I guess as these companies are looking to become more cohesive with maybe things that they've acquired globally, are you seeing and reaching and finding more or additional efficiencies in their businesses? Are those type of conversations happening more frequently, people are actually trying to expand or standardize on a single platform?
Yeah, Joe, this is Jason. I'll take that one. I mean, the simple answer is yes. I mean, there's definitely economy of scale of having one vendor, and then we do provide some consolidated unified reporting for companies that are, you know, for example, using our Tenders product in Europe and, you know, the full suite of products here in the U.S.
And that analytics layer that will sit on top of the global products will continue to expand over time. So, yeah, I mean, we, you know, as I talked about with Moderna specifically on this call, customers are increasingly looking for one vendor who can get their needs across different geographies.
and keep up with the fluid regulatory environment. So that's definitely a tail wing for us. Great, thank you.
keep up with the fluid regulatory environment. So that's definitely a tailwind for us. Great, thank you. Thanks, Joe.
We have time for one last question. Our next question comes from the line of Brian Peterson with Raymond James. Please proceed with your question. Hey, this is Jonathan McCary on for Brian . Thanks for taking the questions here. So with the SaaS transition driving a lot of the recent growth, I'm just kind of curious qualitatively, how do you see that trending after the sun setting of the on-premise solutions? You guys anticipate investing more in the on-premise solutions? I think we're going to have to wait and see. I think we're going to have to wait and see.
of our bookings are actually coming from things other than SAS transitions. And it's really reflective of two things. One, the strong product portfolio we have and the white space opportunity to sell more broadly into a customer who has gone through a SAS conversion. And then of course, the new logo opportunity. So.
You know, we really have seen that I would argue that tipping point really hit last year. And then, as John noted in one of the answers to the prior questions, we have been selectively investing in sales and marketing for life after. Fast transitions and when you put that with the, you know, the product.
component that I just talked about. That really is what's driving the business today. Got it. Thanks.
that I just talked about. That really is what's driving the business today. Got it. Thanks. Thank you.
That concludes our question and answer session. I'd like to turn the call back over to Jason Blessing for closing remarks.
Thank you, operator, and thank you to everyone for joining us today as we discussed on today's call Model N started our fiscal year 2023 with a good quarter and once again delivered strong profitable growth. John and I are going to be out on the road at several investor events this quarter and look forward to seeing many.